A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
At a glance
- Drugs Dovitinib (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- Acronyms DOVE
- 11 Oct 2016 Primary endpoint (Clinical Benefit Rate) has not been met according to the results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 16 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.